Literature DB >> 29356994

Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same.

A J Huq1,2, M Walsh3, B Rajagopalan4, M Finlay5, A H Trainer3,6, F Bonnet7, N Sevenet7,8, I M Winship3,6.   

Abstract

Many cancer predisposition syndromes are preceded or accompanied by a range of typical skin signs. Gorlin syndrome is a rare multisystem inherited disorder which can predispose to basal cell carcinomas (BCCs), childhood medulloblastomas in addition to various developmental abnormalities; the majority of cases are due to mutations in the PTCH1 gene. Approximately 5% of cases have been attributed to a mutation in the SUFU gene. Certain phenotypic features have been identified as being more prevalent in individuals with a SUFU mutation such as childhood medulloblastoma, infundibulocystic BCCs and trichoepitheliomas. Recently hamartomatous skin lesions have also been noted in families with childhood medulloblastoma, a "Gorlin like" phenotype and a SUFU mutation. Here we describe a family previously diagnosed with Gorlin syndrome with a novel SUFU splice site deleterious genetic variant, who have several dermatological features including palmar sclerotic fibromas which has not been described in relation to a SUFU mutation before. We highlight the features more prominent in individuals with a SUFU mutation. It is important to note that emerging therapies for treatment of BCCs in patients with a PTCH1 mutation may not be effective in those with a SUFU mutation.

Entities:  

Keywords:  Basal cell carcinoma; Gorlin syndrome; SUFU; Sclerotic fibroma; Vismodegib

Mesh:

Substances:

Year:  2018        PMID: 29356994     DOI: 10.1007/s10689-018-0073-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  19 in total

1.  Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma.

Authors:  Ingrid Slade; Anne Murray; Sandra Hanks; Ajith Kumar; Lisa Walker; Darren Hargrave; Jenny Douglas; Charles Stiller; Louise Izatt; Nazneen Rahman
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Identification of a SUFU germline mutation in a family with Gorlin syndrome.

Authors:  L Pastorino; P Ghiorzo; S Nasti; L Battistuzzi; R Cusano; C Marzocchi; M L Garrè; M Clementi; G Bianchi Scarrà
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

3.  Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.

Authors:  Miriam J Smith; Christian Beetz; Simon G Williams; Sanjeev S Bhaskar; James O'Sullivan; Beverley Anderson; Sarah B Daly; Jill E Urquhart; Zaynab Bholah; Deemesh Oudit; Edmund Cheesman; Anna Kelsey; Martin G McCabe; William G Newman; D Gareth R Evans
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

4.  Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation.

Authors:  Chihiro Kijima; Toshiyuki Miyashita; Maiko Suzuki; Hidehiro Oka; Kiyotaka Fujii
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

5.  First evidence of genotype-phenotype correlations in Gorlin syndrome.

Authors:  D Gareth Evans; Deemesh Oudit; Miriam J Smith; David Rutkowski; Ernest Allan; William G Newman; John T Lear
Journal:  J Med Genet       Date:  2017-06-08       Impact factor: 6.318

Review 6.  Basal cell carcinomas: attack of the hedgehog.

Authors:  Ervin H Epstein
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

7.  Multiple skin hamartomata: a possible novel clinical presentation of SUFU neoplasia syndrome.

Authors:  Kirsty Mann; Jill Magee; Marine Guillaud-Bataille; Christophe Blondel; Brigitte Bressac-de Paillerets; Josie Yeatman; Ingrid Winship
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

8.  Multiple Hereditary Infundibulocystic Basal Cell Carcinoma Syndrome Associated With a Germline SUFU Mutation.

Authors:  Joshua M Schulman; Dennis H Oh; J Zachary Sanborn; Laura Pincus; Timothy H McCalmont; Raymond J Cho
Journal:  JAMA Dermatol       Date:  2016-03       Impact factor: 10.282

9.  Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-15

Review 10.  Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.

Authors:  Afroz Abidi
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

View more
  4 in total

1.  A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).

Authors:  B J A Verkouteren; B Cosgun; M G H C Reinders; P A W K Kessler; R J Vermeulen; M Klaassens; S Lambrechts; J R van Rheenen; M van Geel; M Vreeburg; K Mosterd
Journal:  Br J Dermatol       Date:  2021-11-08       Impact factor: 11.113

2.  Novel SUFU Frameshift Variant Leading to Meningioma in Three Generations in a Family with Gorlin Syndrome.

Authors:  Gustav Askaner; Ulrikke Lei; Birgitte Bertelsen; Alessandro Venzo; Karin Wadt
Journal:  Case Rep Genet       Date:  2019-07-28

Review 3.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575

Review 4.  Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.

Authors:  Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.